Categories: NewsPharmaceutical

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Wednesday, May 3, 2023, at 4:30 p.m. Eastern Time to discuss first quarter financial results and provide a business update.

To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company’s website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx’s first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https://ardelyx.com/ and connect with us on Twitter, LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

Kimia Keshtbod
kkeshtbod@ardelyx.com

Staff

Recent Posts

CoVet Expands Clinical Leadership with Launch of In-House Medical Department

Veterinary AI leader CoVet introduces a dedicated Medical Department to ensure clinical accuracy, real-world relevance,…

5 hours ago

New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure

ARLINGTON, Va., July 24, 2025 /PRNewswire/ -- The Association of State and Territorial Health Officials…

5 hours ago

Loomis expands its Pharma business by acquiring Kipfer-Logistik

STOCKHOLM, Sweden, July 24, 2025 /PRNewswire/ -- Loomis AB has, through its subsidiary Loomis International…

5 hours ago

HealthArc and PatchRx Partner to Boost Medication Adherence in Pain Management

Integrated RTM solution to deliver real-time medication adherence insights for pain and mental health practices.…

5 hours ago

Loopback Analytics Welcomes Industry Leader Elizabeth Cherry as Vice President of Access Solutions

DALLAS, July 24, 2025 /PRNewswire/ -- Loopback Analytics is excited to welcome Elizabeth Cherry, PharmD,…

5 hours ago

123Invent Inventor Develops Modified Glasses to Assist with Reading (BRA-8028)

PITTSBURGH , July 24, 2025 /PRNewswire/ -- "I wanted to create reading glasses like to no…

5 hours ago